This episode focuses on how GHD presents clinically in pediatric patients across different age groups and the quality-of-life implications of missed or delayed treatment. Dr. Alter explains that in newborns and infants, GHD often manifests as hypoglycemia — since both growth hormone and cortisol maintain blood glucose — and, in male infants, microphallus. Beyond the first few years, GHD typically presents later, most commonly between ages 10 and 13, and the severity of presentation tends to correlate with age of onset. Younger patients are more likely to have organic or structural causes. The panel discusses the challenge of distinguishing true GHD from physiologic pre-pubertal growth deceleration. Dr. Yang notes that in the U.S., there is a tendency to treat borderline cases, whereas European colleagues may take a watch-and-wait approach. Data suggests that roughly half of these pre-pubertal patients may self-correct once puberty begins and retest as normal. When GHD is genuine and left untreated, consequences extend beyond height. Dr. Alter describes improvements in muscle mass, fat distribution, bone health, and cardiovascular markers following GH therapy. Patients — especially those with severe GHD — typically show excitement and marked improvement with treatment. The panel also tackles the nuanced case of a short child with a normal height velocity but a much taller mid-parental target height. Dr. Alter notes that growth genetics are complex (over 180 genes involved) and a comprehensive workup including extended family history is warranted. Treatment decisions must also factor in family preferences, as some families decline GH therapy even when medically indicated. The episode closes with discussion of broader GH indications beyond GHD, including idiopathic short stature (ISS) and other genetic syndromes qualifying for GH therapy. In the next episode, “Diagnosing Growth Hormone Deficiency in Children — Testing, Tools, and Decision-Making,” the panel outlines the step-by-step diagnostic approach to suspected pediatric GHD, including the role of IGF-1, stimulation testing, and imaging.

Recognizing Growth Hormone Deficiency — Symptoms, Presentation, and Quality of Life

This episode focuses on how GHD presents clinically in pediatric patients across different age groups and the quality-of-life implications of missed or delayed treatment.

Dr. Alter explains that in newborns and infants, GHD often manifests as hypoglycemia — since both growth hormone and cortisol maintain blood glucose — and, in male infants, microphallus. Beyond the first few years, GHD typically presents later, most commonly between ages 10 and 13, and the severity of presentation tends to correlate with age of onset. Younger patients are more likely to have organic or structural causes.

The panel discusses the challenge of distinguishing true GHD from physiologic pre-pubertal growth deceleration. Dr. Yang notes that in the U.S., there is a tendency to treat borderline cases, whereas European colleagues may take a watch-and-wait approach. Data suggests that roughly half of these pre-pubertal patients may self-correct once puberty begins and retest as normal.

When GHD is genuine and left untreated, consequences extend beyond height. Dr. Alter describes improvements in muscle mass, fat distribution, bone health, and cardiovascular markers following GH therapy. Patients — especially those with severe GHD — typically show excitement and marked improvement with treatment.

The panel also tackles the nuanced case of a short child with a normal height velocity but a much taller mid-parental target height. Dr. Alter notes that growth genetics are complex (over 180 genes involved) and a comprehensive workup including extended family history is warranted. Treatment decisions must also factor in family preferences, as some families decline GH therapy even when medically indicated.

The episode closes with discussion of broader GH indications beyond GHD, including idiopathic short stature (ISS) and other genetic syndromes qualifying for GH therapy.

Diagnosing Growth Hormone Deficiency in Children — Testing, Tools, and Decision-Making

,” the panel outlines the step-by-step diagnostic approach to suspected pediatric GHD, including the role of IGF-1, stimulation testing, and imaging.

Videos

Endocrinology experts compare pediatric and adult growth hormone deficiency—causes, testing, MRI use, and transition care tips to improve outcomes.

Welcome back to another HCP Live Peer Exchange series. In this episode titled “Unraveling Growth Hormone Deficiency — Etiology and Prevalence,” moderator Dr. Joshua Yang discusses growth hormone deficiency with Dr. Craig Alter, Dr. Jose Garcia, and Dr. Nidhi Agrawal. In this opening episode, the panel introduces the HCP Live Peer Exchange series focused on Managing Growth Hormone Deficiency Across the Continuum of Care. Dr. Joshua Yang sets the stage by outlining the program’s scope, which encompasses diagnosis, treatment decision-making, transition of care, and real-world clinical challenges across both pediatric and adult populations. Dr. Yang begins by discussing the prevalence of GHD in children. Worldwide, GHD affects approximately 1 in 4,000 to 1 in 10,000 children, though in the U.S. the rate is closer to 1 in 3,000 — likely because American clinicians tend to treat milder and moderate cases, and use a higher GH peak cutoff of 10 ng/mL versus the European standard of 7 ng/mL. Dr. Garcia adds that adult GHD is estimated at 1 in 50,000 to 1 in 100,000 individuals, though emerging data suggests higher prevalence — with up to 10–15% of patients with prior head trauma also harboring GHD. The panel then explores etiologies. In children, causes are often congenital (midline defects, pituitary genetic mutations) or idiopathic. Dr. Alter stresses that the primary clinical priority is always accurate diagnosis before treatment — illustrated by a case of a craniopharyngioma initially presenting only as delayed puberty. For adults, structural causes dominate: pituitary adenomas, craniopharyngiomas, radiation, surgery, stroke, or trauma. The episode closes with a discussion of idiopathic pediatric GHD patients — often mild or moderate cases — and the question of whether they carry GHD into adulthood. The consensus is that retesting is essential, and that IGF-1 alone is not reliable enough to confirm or exclude adult GHD. In the next episode, “Recognizing Growth Hormone Deficiency — Symptoms, Presentation, and Quality of Life,” the panel explores how GHD presents at different ages in children and the long-term consequences of undiagnosed or undertreated GHD.

Unraveling Growth Hormone Deficiency — Etiology and Prevalence

Welcome back to another HCP Live Peer Exchange series. In this episode titled “Unraveling Growth Hormone Deficiency — Etiology and Prevalence,” moderator Dr. Joshua Yang discusses growth hormone deficiency with Dr. Craig Alter, Dr. Jose Garcia, and Dr. Nidhi Agrawal.

In this opening episode, the panel introduces the HCP Live Peer Exchange series focused on Managing Growth Hormone Deficiency Across the Continuum of Care. Dr. Joshua Yang sets the stage by outlining the program’s scope, which encompasses diagnosis, treatment decision-making, transition of care, and real-world clinical challenges across both pediatric and adult populations.

Dr. Yang begins by discussing the prevalence of GHD in children. Worldwide, GHD affects approximately 1 in 4,000 to 1 in 10,000 children, though in the U.S. the rate is closer to 1 in 3,000 — likely because American clinicians tend to treat milder and moderate cases, and use a higher GH peak cutoff of 10 ng/mL versus the European standard of 7 ng/mL.

Dr. Garcia adds that adult GHD is estimated at 1 in 50,000 to 1 in 100,000 individuals, though emerging data suggests higher prevalence — with up to 10–15% of patients with prior head trauma also harboring GHD.

The panel then explores etiologies. In children, causes are often congenital (midline defects, pituitary genetic mutations) or idiopathic. Dr. Alter stresses that the primary clinical priority is always accurate diagnosis before treatment — illustrated by a case of a craniopharyngioma initially presenting only as delayed puberty. For adults, structural causes dominate: pituitary adenomas, craniopharyngiomas, radiation, surgery, stroke, or trauma.

The episode closes with a discussion of idiopathic pediatric GHD patients — often mild or moderate cases — and the question of whether they carry GHD into adulthood. The consensus is that retesting is essential, and that IGF-1 alone is not reliable enough to confirm or exclude adult GHD.

,” the panel explores how GHD presents at different ages in children and the long-term consequences of undiagnosed or undertreated GHD.

Experts compare pediatric vs adult growth hormone deficiency—causes, testing, MRI use, and why retesting matters during transition to adult care.

Baba Inusa, MBBS, is a Consultant Paediatrician in the School of Life Course & Population Sciences at King's College London.

Increased Sickle Cell Pain Burden in Sub-Saharan Africa Despite Younger Patients

A multinational SWAY survey is shedding light on disparities and commonalities in symptoms, complications, and quality of life among patients with 

 across sub-Saharan Africa (SSA), low- and middle-income countries (LMICs), and high-income countries (HICs).

The findings suggest that individuals in SSA experience a higher frequency of severe vaso-occlusive crises despite being younger and having more limited access to pain management and supportive therapies, underscoring persistent global gaps in care.

Sickle cell disease disproportionately affects sub-Saharan Africa, where approximately 80% of global cases occur and mortality among children under age 5 ranges from 50% to 80%.

The SWAY data analysis was a multicountry survey conducted between April and October 2019, developed by international SCD experts, patient advocacy groups, and Novartis. The study included 2,145 patients aged 12 years and older across three regions: SSA (n = 519), LMICs (n = 422), and HICs (n = 1,204).

Patients in SSA were younger overall, with a median age of 15 years, compared with 19 years in LMICs and 29 years in HICs.

Speaking to the rationale for the analysis, investigator Baba Inusa, MBBS, Consultant Paediatrician in the School of Life Course & Population Sciences at King’s College London, emphasized the importance of understanding how health system differences shape patient outcomes and care experiences across regions in an interview with 

“We thought it was important that we understand why we are observing those differences, and how those differences can be addressed by different countries, because different countries have different healthcare systems and different approaches in terms of funding and family structures,” said Inusa.

Symptom burden and clinical complications

Across all regions, patients reported broadly similar symptom patterns and complications, suggesting a shared clinical phenotype of sickle cell disease globally. The most commonly reported symptoms included fatigue (34%–77%), headache (39%–58%), and bone aches (32%–58%).

Complications were also consistently reported across settings, including fever (60%–75%), infections (37%–66%), and joint-related issues (29%–65%), reinforcing the multisystem nature of the disease regardless of geographic region.

Vaso-occlusive crises and acute disease burden

Despite similar overall symptom patterns, notable differences emerged in acute disease burden. The proportion of patients experiencing more than five vaso-occlusive crises (VOCs) in the prior year was highest in SSA at 30%, compared with 22% in LMICs and 27% in HICs.

Importantly, this higher burden of recurrent VOCs occurred in a younger SSA population, highlighting a disproportionate severity of acute disease despite earlier age distribution in the cohort.

Treatment access and care-seeking behavior

Marked disparities were also observed in treatment utilization and care-seeking patterns across regions. Opioid use was substantially lower in SSA at 26%, compared with 73% in HICs. Use of over-the-counter analgesics followed a similar trend, reported in 30% of SSA patients versus 63% in LMICs and 64% in HICs.

Care delivery patterns further reflected structural differences in health systems and access to services.

“In Africa, the majority of patients tended to undergo treatment at home. If they had pain or other episodes, they treated it at home, whereas patients in Europe and the US tend to go to the hospital and often have periods of admission,” said Inusa.

Overall, the SWAY analysis highlights both shared and divergent experiences of sickle cell disease across global regions. While symptom profiles and complications were broadly consistent, significant disparities emerged in vaso-occlusive crisis frequency, treatment access, and care-seeking behavior.

Findings underscore that patients in sub-Saharan Africa experience a higher burden of acute vaso-occlusive events despite being younger, alongside substantially more limited access to pain management and supportive therapies—reinforcing persistent inequities in sickle cell disease care worldwide.

Editor’s Note: Inusa reports relevant disclosures with Novo Nordisk A/S.

Inusa B, Andemariam B, Minniti C, et al. Sickle Cell Disease Burden in Sub-Saharan Africa Compared to Other Regions: Results from the SWAY Survey. 

. Published online April 2026:100092. doi:

https://doi.org/10.1016/j.bglo.2026.100092

Adigwe OP, Onoja SO, Onavbavba G. A Critical Review of Sickle Cell Disease Burden and Challenges in Sub-Saharan Africa. 

Study investigator Inusa explains the gap in sickle cell disease findings from SWAP, a multinational survey. 

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Hematology

Sickle Cell

Sickle Cell condition center page, resources on the topics of medical news and expert insight into sickle cell disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sickle cell research, treatment, and drug development.

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Implementing Automated Insulin Delivery in Type 2 Diabetes, With Diana Isaacs, PharmD

Despite relatively limited uptake, recent research has shown the efficacy of automated insulin delivery (AID) systems in patients with 

Association of Clinical Endocrinology (AACE) Annual Meeting 2026

 in Las Vegas, Nevada, Diana Isaacs, PharmD, director of education and training in diabetes technology at Cleveland Clinic, presented a statement on the benefits of implementing AID devices in T2D care – and the importance of knowing the full breadth of options available for a given patient.

“With T2D, we have 3 algorithms that have been approved; however, we actually have 5 algorithms total, and we have 6 different insulin pumps that can be options,” Isaacs told 

 in an exclusive interview. “There are definitely a lot of choices, and I believe that we as healthcare professionals shouldn’t necessarily choose for the person. But it is up to us to know what’s out there, so we can present the different options.”

Clinical guidelines have lately begun including AID devices among treatment recommendations for patients; recently, the American Diabetes Association released the 2026 Standards of Care in Diabetes, which included a series of revisions to the prior document. Among these was a statement that AID systems are the preferred delivery system for both adult and child patients with T2D on multiple daily injections or sensor-augmented pump therapy. Additionally, the new guidelines recommend the consideration of AID systems in patients with T2D on basal insulin who fail to meet individualized glycemic goals.

Additionally, in a recent 13-week multicenter trial, investigators determined that adults with T2D treated with AID saw a greater reduction in glycated hemoglobin levels than via continuous glucose monitoring (CGM) alone. The study enrolled 319 patients, randomly assigned in a 2:1 ratio to receive either AID or to continue their pretrial insulin delivery method. Both groups received CGM throughout the trial.

Ultimately, glycated hemoglobin dropped by 0.9 percentage points (from 8.2+/-1.4% at baseline to 7.3+/-0.9% at week 13) in the AID group and by 0.3 percentage points (from 8.1+/-1.2% to 7.7+/-1.1%) in the control group (mean adjusted difference, -0.6 percentage points; 95% CI, -0.8 to -0.4; 

 <.001). The mean time in range for patients also increased in the AID group and control group, respectively. All other multiplicity-controlled outcomes measured substantially better in the AID group as well. The trial ultimately displayed the efficacy of AID devices in T2D, underscoring the revised treatment guidelines.

Isaacs also discussed the interplay between AID pumps and more prominent T2D treatments, such as GLP-1 RAs and SGLT2 inhibitors. Given their substantial and well-established efficacy, Isaacs notes that these medications are in no way being superseded by insulin – rather, clinicians should manage these treatments in tandem.

“In T2D, we want to optimize GLP-1 agonists and SGLT2 inhibitors,” Isaacs said. “When you look at the guidelines, GLP-1 drugs should be offered and used before insulin is even started. These drugs are essential, and we’re not suggesting that pumps would ever replace them. The beautiful thing about these pumps is that they’re constantly adjusting insulin, so they’re very good at being able to back off the insulin as needed as these drugs are added.”

Editors’ Note: Isaacs reports disclosures with Abbott, Sanofi, Insulet, Mannkind, Lilly, Novo Nordisk, and others.

Aleppo G, Isaacs D. Insulin Pumps for Type 2 Diabetes. Presented at the American Association of Clinical Endocrinology Annual Meeting 2026, Las Vegas, NV. April 22-24, 2026.

American Diabetes Association Professional Practice Committee for Diabetes*. Summary of Revisions: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(1 Suppl 1):S6-S12. 

Kudva YC, Raghinaru D, Lum JW, et al. A randomized trial of automated insulin delivery in type 2 diabetes. New England Journal of Medicine. 2025;392(18):1801-1812. 

Isaacs covers the range of AID devices currently available and approved for T2D, providing suggestions for implementation and continuous glycated hemoglobin monitoring.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 2 Diabetes

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Strategic Alliance Partnership

 of a Biologics License Application (BLA) for imsidolimab in generalized pustular psoriasis (GPP) was announced, the 

 editorial team spoke in an interview with a dermatology leader regarding this move’s significance for patients with GPP.

Vanda Pharmaceuticals' investigational interleukin (IL)-36 receptor inhibitor could potentially add to the limited armamentarium of agents implemented within the GPP patient population. The medication is currently under formal review by the agency as a potential addition to the emerging class of IL-36–targeted drugs in the dermatology space.

Neal Bhatia, MD, a dermatologist at Therapeutics Clinical Research whose location served as an investigator site for the development of spesolimab (Spevigo; Boehringer Ingelheim), the first IL-36 receptor inhibitor approved for GPP, spoke in this Q&A interview about this new announcement regarding imsidolimab:

I wanted to ask you a little bit about the FDA’s acceptance of the BLA for imsidolimab and the significance of this move. What might this mean for patients with generalized pustular psoriasis, and how significant would you say it is for clinicians to see another therapy targeting the IL-36 pathway?

 I think it's actually very novel and well-timed. We were an investigator site for the Boehringer Ingelheim drug, which is now spesolimab. That was the first IL-36 to make it to dermatology for us, which was great to have another molecule, which is even better, and adds to the significance. Leo Pharma now brings spesolimab map to the market for us and they've done a good job with that. That being said, Vanda makes good drugs, from what I understand. I think this is another one where the GEMINI trials. 53% of the patients got to clear or almost clear by Week 4.

For many of these patients who suffer in a prison of misdiagnosis or just not having options, it is really some game-changing stuff for them. More importantly, we're understanding how rapidly the disease can be mitigated with the onset of the intravenous dosage. We saw that with the Effisayil 2 trials and the Effisayil 1 trial as well, and it brought them both to relevance. The Effisayil 2 trials, specifically with the SubQ to keep things away…I think what imsidolimab is showing us is that it's got a very similar destiny, if you will. Clinically, thinking about durability, the 2-year maintenance period without flares is a significant improvement from what we know from a patient's quality of life standpoint.

My biggest take home point is that I hear a lot about a lot of dermatologists say, ‘Well, my patients got better with a 17 inhibitor or a 23 inhibitor.’ From a psoriasis pathway, there is always a little bit of overlap. What interleukin-17, what IL-23 does, and what some crossovers like IL-22 are involved with is that they're all intermixed into it. There's going to be a little impact from what targeting those cytokines can do. But GPP is well established in an interleukin-36 milieu, where that cytokine is the main driver. You see a lot of neutrophils and a lot of reactive oxygen species, a lot of tissue damage. All of that is unique to the IL-36 pathway, and by inhibiting that, just like we saw with spesolimab, we'll see that with imsidolimab. We can make real headway in keeping the disease away. Not just making it go away.

You mentioned to the 53% of patients attained clear or almost clear skin by Week 4. How meaningful would you say that level of rapid response is for clinicians managing acute GPP flares?

You can look at it from the dermatologist's side as well as the patient's side. Obviously, from the patient side, if they have had no relief of the pain of the visceral symptoms, the fevers, the misery that they go through with the pustules, this will be a godsend for them. I would say that first and foremost, a lot of these patients just live in fear of their next flare. Even when their flare is put out, the first thing they do is worry about when the next one is. Again, that is the nature of the disorder. I think even more so, to see some quick onset of relief, it should take away the thought process of turning to a 17 inhibitor or 23 inhibitor, when that isn't the pathway of choice, and it's not really what we see under the hood for GPP. With the label of psoriasis under generalized pustular psoriasis, there's going to be a mindset that says, ‘Sure, these psoriasis drugs should work.’ But I think we've seen enough data, as well as seen enough mechanism of action discussion, that we know that the inhibition of the 36 pathway is really the key to success for these patients.

 From a clinical perspective, how important is the reported durability of response over the roughly 2-year maintenance period with flares in the active treatment arm?

If we can put out the flares and give patients some relief of their potential onset, that's a very significant win for how this drug could impact the market. Understanding 2 years [of maintenance] for patients who have had this disease, you can imagine what that does to quality of life. We talk about quality, like for eczema, psoriasis, and other disorders like hidradenitis, and these are all very significant. But from what we've seen of GPP, we haven't had an option that has really been a benefit. We've seen cyclosporine and some of these other Th1 drugs go after that process, which is incomplete. They're slow-acting, and they come with their own baggage. So, to see where we can get some real relief from what the GEMINI trials showed us, as well as what we can see in the 2-year data, I think we have a lot of opportunities to put out fires that didn't get put out before.

 If it is approved by the FDA, where do you think imsidolimab could fit within the current treatment landscape for GPP?

If you look at, you know, spesolimab against the current market-approved treatments, it would probably be side-by-side with that. I would hope that the dermatologists are understanding that that pathway is not the pathway that affects GPP, even though there may be some anecdotal evidence. A lot of dermatologists will say, ‘Oh, sure, my patients do better on 17, 23,’ as I said, and for me, that makes sense, because you have easy access to it. You have easy access to a sample of it to get them started. But if that is the way to get the ball rolling and then get them on an IL-36-modifying treatment, I think that would be a paradigm that would actually make a lot of sense.

Given the rarity and the severity of GPP, how might a therapy with a favorable safety profile and low incidence of anti-drug antibodies influence treatment decision-making in clinical practice?

 I think the first key is just making the diagnosis. Get that diagnosis confirmed. I would give the patient their own path report so that they carry it around in case they run into trouble, or they get into an emergency room or urgent care where they can't get treated. They can show whoever has seen them that this is their diagnosis. I think the other key to the equation, too, is to get them to a place where infusion can be as easy as possible, or at least have access to the drug within a day or 2, to try to get them out of the flare.

Really thinking about the big picture for the dermatologist is being an advocate for these patients, saying, ‘Look, this is a rare disease. This is not just a variant of psoriasis that I can try to knock down with other therapies that I have samples of.’ I think even more so, just to support the research as well as the approval of some of these newer therapies and say, ‘Well, we're going to welcome those into dermatology and not give these away to rheumatologists and oncologists.’ Because that's where we lose our edge on our specialty. That would just be a shame.

The quotes contained in this summary were edited for the purposes of clarity.

Bhatia reported serving as an advisor, consultant, and investigator for AbbVie, Almirall, Arcutis Biotherapeutics, Beiersdorf, Biofrontera, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant Sciences, EPI Health, Ferndale, Galderma, Incyte, ISDIN, Johnson & Johnson, La Roche-Posay, LEO Pharma, Lilly, Ortho Dermatologics, Pfizer, Regeneron Pharmaceuticals, Sanofi, Sun Pharma, and Verrica Pharmaceuticals.

Smith T. FDA Accepts BLA for Imsidolimab as Generalized Pustular Psoriasis Treatment. HCPLive. February 25, 2026. Accessed April 28, 2026. 

https://www.hcplive.com/view/fda-accepts-bla-imsidolimab-generalized-pustular-psoriasis-treatment.

Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis. Vanda Pharmaceuticals, Inc. February 25, 2026. Accessed April 28, 2026. 

https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-fda-acceptance-of-biologics-license-application-filing-for-imsidolimab-for-the-treatment-of-generalized-pustular-psoriasis-302696991.html

Articles

FDA acceptance of a BLA places imsidolimab, an investigational IL‑36 receptor inhibitor, under review as a second targeted option for generalized pustular psoriasis alongside spesolimab. GEMINI results showed 53% achieving clear/almost clear skin by week 4, supporting rapid control of painful systemic flares. Reported durability with roughly two years of maintenance without flares could meaningfully improve quality of life versus slower, toxic immunosuppressants. Emphasis remains on correct diagnosis, timely infusion access, and prioritizing IL‑36 over IL‑17/23 off‑pathway use in routine practice.

In this Q&A interview, Bhatia discusses the FDA's recent acceptance of BLA for imsidolimab for generalized pustular psoriasis (GPP).

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Q&A: Discussing Imsidolimab for Generalized Pustular Psoriasis, With Neal Bhatia, MD

Andrea Cipriani, MD, PhD, from the University of Oxford.

Study showed the PETRUSHKA decision-support tool reduced antidepressant discontinuation, supporting personalized treatment approaches.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

PETRUSHKA Tool Improves Antidepressant Persistence in MDD, With Andrea Cipriani, MD, PhD

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

The FDA has approved budesonide/glycopyrrolate/formoterol fumarate as the first single-inhaler triple therapy for asthma.

FDA News

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

FDA Approves BGF Triple Therapy for Asthma in Patients 12 and Older

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

AbbVie submitted an sNDA to the FDA seeking approval of upadacitinib for severe alopecia areata in adults and adolescents.

Alopecia

Upadacitinib sNDA Submitted to FDA for Severe Alopecia Areata

Yao Wei Lu, PhD, assistant professor of medicine and member of the Hastings Center for Pulmonary Research at the Keck School of Medicine of USC

yao wei lu.jpeg

Lu explains findings that link PCBP1 to the pathogenesis of AARS2-related cardiomyopathy. 

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

New Target Emerges for AARS2-Related Cardiomyopathy With Early-Life Mortality

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

The FDA granted Fast Track Designation to coramitug, an investigational anti-TTR antibody designed to clear existing amyloid deposits in ATTR cardiomyopathy.

Cardiomyopathy

FDA Grants Fast Track to Coramitug for ATTR-CM, Supporting Amyloid-Clearing Phase 3 Trial

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

The FDA has accepted bepirovirsen's NDA for Priority Review and granted Breakthrough Therapy designation, with a PDUFA date of October 26, 2026.

Hepatology

Hepatitis C

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.

FDA Grants Bepirovirsen Breakthrough Therapy Designation, Priority Review for Chronic Hepatitis B

The phase 3 trials enrolled frequent exacerbators regardless of eosinophil count or smoking status.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

OBERON and TITANIA Showcase Tozorakimab's Emerging Benefit for COPD, With Frank Sciurba, MD

Aleena Banerji, MD, professor at Harvard Medical School and director of clinical care at the Center for Drug and Vaccine Allergy at Massachusetts General Hospital.

Phase 3 HAELO data show an 87% reduction in hereditary angioedema attack rates with a one-time CRISPR therapy. Banerji discusses efficacy, safety, and durability.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Single-Dose Lonvo-z Cuts HAE Attacks by 87% in Phase 3 Trial, With Aleena Banerji, MD

Stay updated with the latest healthcare breakthroughs, including FDA actions and new topline clinical trial data, in this week’s essential news roundup.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

The HCPFive: Top News for Healthcare Providers from the Week of 04/19

These Week 16, phase 2a findings from the EVERLAST-A study assessing ORKA-001 highlight the treatment's potential in those with plaque psoriasis.

Latest News

Recognizing Growth Hormone Deficiency — Symptoms, Presentation, and Quality of Life

Unraveling Growth Hormone Deficiency — Etiology and Prevalence

Increased Sickle Cell Pain Burden in Sub-Saharan Africa Despite Younger Patients

Implementing Automated Insulin Delivery in Type 2 Diabetes, With Diana Isaacs, PharmD

Q&A: Discussing Imsidolimab for Generalized Pustular Psoriasis, With Neal Bhatia, MD